Replies to post #11292 on ANI Pharmaceuticals (ANIP)

[jacob613]

I need to peruse the post restructured MNK balance sheet more closely, but I’m not sure that it has such tremendous financial“flexibility” like a MSFT to just cut prices 50% + to drive away competition. They need CORTI whole dollar profits to service interest last I checked. But let’s play: let’s say market size is 500mm at ~20k a vial (down 50%) and Ani offers at 10k as per AP (prices down 1/2), so if ANI Gets 30% of market thats 75mm revenues and at least $50mm ebitda. That brings EBITDA to $130mm which means stock is trading 4.5x’s ebitda. If the stock revals back to 7.5x, that’s $71 pt

[jacob613]

Btw, Corti was purchased back in 2016, why has the process taken this long? I’m not sure I get it. I think the stock assumes either Cort isn’t happening or will be very delayed at $30.
Sad.
For me.

[jeffqdhsr]

Good assessment !

IMO MNK has many challenges to overcome & yes bankruptcy is a real possibility , & IMO this will hang over their head for some time to come. Will Archer make a offer for Corti ? Sounds plausible right & why not, unless it’s not for sale. Uncertainties with MNK is

Leaving a huge opportunity for ANI to fill that gap, it’s possible they will take the lion share of market ; if Corti is approved

I am picking ANI as my horse to win !

[pcinsurto]

@LordDarley: I respectfully disagree.
Medicaid net sales for Acthar Gel, currently contributes only 10% to total Acthar sales

The 600m is a retroactive number.

Corti is still a huge win for ANIP when approved.

[big bambino]

Here, Here.